945 results on '"Van Der Wall, Elsken"'
Search Results
2. Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial
3. Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study
4. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer
5. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference—a Dutch population-based study from 2008 to 2018
6. Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?
7. Time Trends in Histopathological Findings in Mammaplasty Specimens in a Dutch Academic Pathology Laboratory
8. Design of a multinational randomized controlled trial to assess the effects of structured and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life: the EFFECT study
9. Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?
10. Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.
11. Receptor status of breast cancer diagnosed during pregnancy: A literature review
12. The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis
13. Cytoplasmic DDX3 as prognosticator in male breast cancer
14. The effect of an e-learning module on grading variation of (pre)malignant breast lesions
15. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
16. Physical Fitness and Chemotherapy Tolerance in Patients with Early-Stage Breast Cancer
17. Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study
18. Off to a good start after a cancer diagnosis: implementation of a time out consultation in primary care before cancer treatment decision
19. Addressing challenges in information-provision: a qualitative study among oncologists and women with advanced breast cancer
20. Physical Fitness and Chemotherapy Tolerance in Patients with Early-Stage Breast Cancer
21. Effect of Physical Exercise on MRI‐Assessed Brain Perfusion in Chemotherapy‐Treated Breast Cancer Patients: A Randomized Controlled Trial.
22. Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands
23. Effects of exercise during chemotherapy for breast cancer on long-term cardiovascular toxicity
24. Grading variation in 2,934 patients with ductal carcinoma in situ of the breast: the effect of laboratory- and pathologist-specific feedback reports
25. Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy
26. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018
27. Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
28. Effects of exercise during chemotherapy for breast cancer on long-term cardiovascular toxicity
29. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer
30. Time Trends in Histopathological Findings in Mammaplasty Specimens in a Dutch Academic Pathology Laboratory
31. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study
32. Effects of Tamoxifen and Exemestane on Cognitive Function in Postmenopausal Patients with Breast Cancer
33. Can nocebo information and empathy alleviate symptoms in advanced cancer? An video-vignette study
34. Data from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer
35. Supplementary Figure 1 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
36. Supplementary Figure 7 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
37. Supplementary Figure 6 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
38. Supplemental Movie S1. Explanatory Movie of Multiplex Advanced Pathology Imaging (MAPI). from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
39. Supplementary Figure 4 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
40. Supplementary Figure 5 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
41. Supplemental Materials and Methods and Supplementary Figures 1 and 2 from Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer
42. Supplementary Figure 3 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
43. Supplementary Figure 2 from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
44. Supplemental Material and Methods from Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study
45. Supplementary Figure 2 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling
46. Supplementary Figure 3 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling
47. Supplementary Figure Legends from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling
48. Supplementary Figure 5 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling
49. Supplementary Figure 6 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling
50. Supplementary Figure 1 from Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.